Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases.
Rezolute has raised $96.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2025.
Rezolute's investors include Great Point Partners, Blackstone Group, Biotechnology Value Fund, SLR Capital Partners, Ildong Pharmaceutical.
Rezolute is headquartered in Louisville, United States.
Rezolute is a clinical-stage biopharma specializing in the development of drug therapies for patients with metabolic and orphan diseases.
Rezolute is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rezolute — Funding & Investors." VCBacked, April 23, 2025, https://www.vcbacked.co/company/rezolute. Accessed September 30, 2026.
VCBacked. (2025). Rezolute — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/rezolute
{{cite web |title=Rezolute — Funding & Investors |url=https://www.vcbacked.co/company/rezolute |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated